Conference Reports for NATAP

Back

59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Oct 31-Nov 1 2008 San Francisco, CA     Viral Responses in African Americans, Latinos, and Caucasians in the US Phase 2 Study (PROVE1) of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1-Infected Patients with Hepatitis C - (9/29/09)   Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection - (01/21/09)   Results of A Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, A Non-nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers - (01/21/09)   In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance - (01/20/09)   Pattern of serial HBV DNA level and HCC development in Patients with Liver Cirrhosis - (12/19/08)   REVIEW OF SELECTED LIVER CANCER ABSTRACTS FROM THE AASLD MEETING IN SF 2008 FOR NATAP - written by Robert Gish MD and Catherine Frenette MD CPMC (12/19/08)   Evaluation of a 4 Week Lead-in Phase with Nitazoxanide (NTZ) prior to Peginterferon (PegIFN) plus NTZ for Treatment of Chronic Hepatitis C: Final Report - (12/10/08)   On-Treatment HBsAg Decline During Peginterferon alfa-2a (40KD) ± Lamivudine in Patients With HBsAg-Positive CHB As A Potential Predictor Of Durable Off-Treatment Response - (12/05/08)   Efficacy And Safety Of Peginterferon Alfa-2a Versus Adefovir Dipivoxil (ADV) In Treating Lamivudine Resistant HBeAg-Positive CHB: An Interim Analysis Of A Prospective Randomized Study - (12/05/08)   Response Patterns Of Chinese Patients With Chronic Hepatitis B Who Achieved HBsAg Clearance Through Treatment With Peginterferon Alfa-2a - (12/05/08)   A Multicenter, Open-Label Study Of Efficacy And Safety Of Peginterferon Alfa-2a (40KD) In Korean Patients With HBeAg-Positive CHB Harboring Lamivudine-Resistant YMDD Mutants - (12/05/08)   Correlation Between HBV cccDNA And HBsAg Levels And Their Reduction By Peginterferon Alfa-2a-Based Therapy In Patients With Chronic Hepatitis B - (12/01/08)   In Patients With HBeAg-Negative Chronic Hepatitis B, HBsAg Serum Levels Early During Treatment With Peginterferon Alfa-2a Predict HBsAg Clearance up to 4 Years Post-Treatment - (12/01/08)   Kinetics Of HBsAg Decline During And Following Treatment of CHB: Early And Rapid HBsAg Decline During Peginterferon alfa-2a Is Predictive Of HBsAg Clearance - (12/01/08)   Kinetics Of HBsAg Decline in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Peginterferon alfa-2a According to Genotype and its Association With Sustained HBsAg Clearance 4 Years Post Treatment - (12/01/08)   Quantitative Assessment Of Serum HBsAg Levels Using The Elecsys HBsAg II Screening Assay: Results Of A Feasibility Study - (12/01/08)   Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study - (12/01/08)   A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of the NS3/4A Protease Inhibitor ITMN-191 in Healthy Subjects - (12/01/08)   Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships for ITMN-191 in a Phase 1 Multiple Ascending Dose (MAD) Trial in Patients with Genotype 1 Chronic Hepatitis C Infection - (12/01/08)   In Vitro activity and pharmacological properties of IDX375, a novel HCV non-nucleoside inhibitor - (12/01/08)   A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study - (11/26/08)   Probability of virologic relapse during follow-up varies with the rapidity of the on-treatment virologic response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin - (11/26/08)   Prediction of SVR in HCV genotype 1 patients co-infected with HIV based on virologic responses at week 4 and 12 of treatment with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS): Retrospective analysis of APRICOT - (11/26/08)   Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-naïve Patients with Genotype 1 Hepatitis C: Week 12 Interim Results - (11/26/08)   Randomized study comparing Peginterferon alfa2a plus Ribavirin and Peginterferon alfa2b plus Ribavirin in naïve patients with chronic hepatitis C: Final results of the MiIan Safety and Tolerability (MIST) Study - (11/24/08)   Metformin with Peginterferon Alfa-2a and Ribavirin in the Treatment of Naive Genotype 1 Chronic Hepatitis C Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and Double-Blinded Trial - (11/21/08)   SVR in African American Patients: Results of the IDEAL Study (Individualized Dosing Efficacy vs Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) - (11/21/08)   A Study of Telaprevir Combined with Peginterferon Alfa-2a and Ribavirin in Patients with Well-documented Non-response or Relapse After Previous Peginterferon Alfa-2a and Ribavirin Treatment: Interim Analysis - (11/20/08)   New Data Suggest Long-Term Treatment with BARACLUDE (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B - (11/17/08)   Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD - (11/17/08)   PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B - (11/17/08)   Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103 - (11/17/08)   Evaluation of Long-term Entecavir Treatment in Stable Chronic Hepatitis B Patients Switched from Lamivudine Therapy - (11/17/08)   Three Years of Entecavir (ETV) Re-treatment of HBeAg(-) ETV Patients Who Previously Discontinued Treatment: Results from Study ETV-901 - (11/17/08)   Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection - (11/14/08)   Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects (1910) - (11/14/08)   Histologic Assessment of Long-term Entecavir Treatmentin Chronic Hepatitis B Patients - (11/14/08)   Five Years of Continuous Entecavir for Nucleoside-naïve HBeAg(+) Chronic Hepatitis B: Results from Studies ETV-022/-901 - (11/14/08)   Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901 - (11/14/08)   Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants - (11/12/08)   Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects (1910) - (11/11/08)   Pharmacokinetics of once-daily regimens of the novel HCV NS3/4A-protease inhibitor TMC435350, with and without peg-IFN and ribavirin, in HCV-infected individuals - (11/11/08)   Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6 - (11/11/08)   Potent Antiviral Response To The HCV Nucleoside Polymerase Inhibitor R7128 For 28 Days With Peg-IFN And Ribavirin: Subanalysis by Race/Ethnicity, Weight and HCV Genotype - (11/07/08)   New HCV Drugs at AASLD: Vertex is Focus at Hepatitis C Meeting - (11/07/08)   Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor R7128 In HCV Genotype 2 and 3 Prior Non-Responders: Results Of R7128 1500mg BID With PEG-IFN And Ribavirin For 28 Days - (11/07/08)   Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD - (11/07/08)   Antiviral Activity of the HCV Polymerase Inhibitor PF-00868554 Administered as Monotherapy in HCV Genotype 1 Infected Subjects - (11/07/08)   Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103) - (11/06/08)   Telaprevir in Combination with Peginterferon-a-2a With or Without Ribavirin in the Treatment of Chronic Hepatitis C Treatment-Naïve Genotype 1: Final Results of the PROVE2 Study (conducted in Europe) - (11/06/08)   A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results - (11/06/08)   Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R) - (11/06/08)   Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Patients with the NS3/4A Protease Inhibitor ITMN-191 Leads to Rapid Reductions in Plasma HCV RNA: Results of a Phase 1b Multiple Ascending Dose (MAD) Study - (11/05/08)   Intravenous silibinin for treatment of nonresponders to peginterferon/ribavirin therapy in chronic hepatitis C - (11/05/08)   Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients - (11/04/08)   Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection - (11/04/08)   GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance And Increases RVR Rates In Phase 2 Clinical Trial - (11/04/08)   Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study - (11/04/08)   BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study - (11/04/08)   An On-going Outbreak of Acute HCV in HIV-infected Men in New York City: Rates of Spontaneous Clearance, Treatment Responses, and Liver Fibrosis - (11/3/08)   New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection - (11/3/08)   Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients - (11/3/08)   TIBOTEC PRESENTS INTERIM FINDINGS FOR TMC435, AN INVESTIGATIONAL GENOTYPE 1 HEPATITIS C TREATMENT, AT THE AASLD LIVER MEETING 2008 - (11/3/08)   GILEAD ANNOUNCES TWO-YEAR DATA FROM PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR CHRONIC HEPATITIS B - (11/3/08)